HealthLinx makes a push into Chinese market

HealthLinx has its eyes set on the ballooning Chinese market with its ovarian cancer therapy, OvPlex. To that end, the Melbourne-based biopharma company has entered a research agreement with Chinese CRO CtyogenDx, which specializes in getting clinical clearance for imported products.

The two will begin a 350-patient study of OvPlex in the Wuxi and Shanghai districts. Following the study, the intention is to proceed with State Food and Drug Administration (SFDA) approval to have OvPlex registered for sale in China.

HealthLinx and CytogenDX will co-fund the study which will take 9-12 months to complete and is seen as the precursor to obtaining SFDA approvals.

“China is potentially a huge market for OvPlex so the commencement of the study is excellent news for the company and its shareholders,” said HealthLinx managing director Nick Gatsios.

“CytogenDX is a highly respected healthcare company in the Chinese market working with groups to conduct clinical trials and then proceeding with SFDA approvals and distribution of products throughout China.”

You can read more about Australian-Chinese partnerships in biotechnology in the upcoming September-October print edition of Australian Life Scientist.